Clonogenic assays in the B16 melanoma: response to cyclophosphamide. by Steel, G. G. et al.
Br. J. Cancer (1977) 36, 618
CLONOGENIC ASSAYS IN THE B16 MELANOMA:
RESPONSE TO CYCLOPHOSPHAMIDE
G. G'. STEEL, K. ADAMS AND T. C. STEPHENS
From the Radiotherapy Research Department, Divisions of Radiotherapy and Biophysics,
Institute of Cancer Research, Sutton, Surrey
Receivedl 9 June 1977 Accepte(d 30 Jinie 1977
Summary.-The survival of clonogenic cells in the B16 melanoma has been studied
simultaneously by 3 methods: an in vitro assay in soft agar, a lung-colony assay, and
bythe end-point dilution technique. Details ofthe first2 methods havepreviouslybeen
reported, but those of the third are described here. The 3 methods have agreed well
in investigations of the response of the B16 melanoma to cyclophosphamide.
THE B16 melanoma has beenextensively
used for studies in experimental chemo-
therapy (Griswold, 1972, 1975) and has
been included in the National Cancer
Institute screening programme for chemo-
therapeutic agents. Our interest has been
in the development and application of
assays for clonogenic cells within experi-
mental tumours, and results on the Lewis
lung tumour have already been described
(Steel and Adams, 1975). The B16 mela-
noma has proved to be a highly trans-
plantable tumour that is easily assayed for
clonogenic cell survival. The present paper
describes its performance in 3 different
assays and the results that have been
obtained in studying its response to single
doses of cyclophosphamide (CY).
MATERIALS AND METHODS
B16 mnelanomia. Specimens of the B16
melanoma were originally obtained from the
Jackson Laboratory, Bar Harbor, Maine, in
1970. Apart from a period of a few months
wrhen it was stored in liquid N2, it has since
that time been passaged in C57BL mice ofthe
Institute ofCancer Research colony, in which
all the present work wNas performed. Macro-
scopically, the tumour tissue has generally
been black or dark grey. Variations in black-
ness have occurred, and it has seemed that
when passaged by means of trypsinized cell
suspensions the tumour has tended to
become whiter. We have therefore routinely
passaged by intramuscular (i.m.) injections of
tumour homogenate. Tumours were dissected
out, chopped finely with crossed scalpels, and
then forced through needles of decreasing
diameter. The homogenate wNas washed in
balanced salt solution and finally suspended
in 10 volumes of tissue culture medium.
Recipient mice were injected bilaterally into
the gastrocnemius muscles of the hind legs
with 0-02-ml volumes of the homogenate. No
such implants have failed to take. For some
experiments, s.c. implants have been used,
but the tumours tended to be more necrotic
than when grown i.m.
Cell suspensiot technique.-Tumour tissue
wAas dissected out and chopped using crossed
scalpels. After washing the tissue in phos-
phate-buffered saline (PBS) it wvas digested in
PBS containing 0 25% Bacto-trypsin (Difco
Laboratories) -+- 01 mg/ml DNAse (Sigma).
Following an initial 10-min incubation to
remove damaged cells, the main incubation
lasted 40 min, after which the tissue frag-
ments were transferred to fresh PBS and
given a few hard shakes to dislodge mininally-
trypsinized cells from the surface of the
fragments. These cells were washed in Eagle's
basal medium (Biocult Laboratories) to which
had been added antibiotics (sodium benzyl
penicillin 60 jug/ml, neomycin sulphate 50 ytg/
ml, streptomycin sulphate 100 Hug/ml and
foetal calf serum, 10% by volume. The cells
were filtered through a 400-mesh stainless
steel gauze, counted in a haemocytometer
under phase contrast, and diluted as requiredCYCLOPHOSPHAMIDE AND B16 MELANOMA
in Eagle's medium plus serum. Viability, as
judged by the intactness ofthe cell membrane
and a bright halo under phase contrast, was
usually in excess of 9000. The yield of viable
cells was usually in the range 5 x 107 to
108/g wet tissue.
RESULTS
Growth rate
A growth curve for s.c. implants of B16
melanoma is shown in Fig. 1. It was
obtained on 2 groups of 10 tumours
whose superficial dimensions were trans-
formed into estimated tumour weights
using a calibration-curve technique (Steel
and Adams, 1975). The full line is a
Gompertz equation, fitted to the data by
a least-squares method, from which the
volume-doubling time can be calculated as
2-5 days at 01 g and 4-0 days at 1-0 g.
Experiments have been performed to
investigate whether the presence of a
large B16 tumour in one part of an animal
influences the growth of a small tumour
elsewhere. S.c. tumours were implanted
into the left flank ofgroups of 10 mice and
allowed to grow for 17 davs, by which
50
20H
time they had reached a size of approxi-
mately 0-1 g. Inocula of 104 or 106 cells
were then injected into the right flanks of
thetumour-bearingmice, andintocontrols,
and the growth of these implants was
followed for a further 14-17 days, by
which time the tumours in the left flank
had reached
- 2-3 g. There was no
significant difference in any of these
experiments between the growth of the
test tumours in tumour-bearing or non-
tumour-bearing hosts.
End-point dilution assa?y
A "master" cell suspension was pre-
pared, containing -, 2 x 106 cells/ml and
accurately counted in a haemocytometer.
Serial dilutions were made, using dis-
posable glass pipettes whose calibration
had been checked by weighing, and at
least 10 implants were made of 0*05-ml
aliquots from each of a selected range of
dilutions, attempting to embrace the
point of 500o tumour takes (Hewitt,
1953). The mice were observed for a
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Fie. 1. Growth curve for s.c.-implanted B16
melanomas. The full line is a Gompertz
curve, fitted to the data.
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FiG. 2.-The relationship between implant
take probability and the number of viable
B16 cells implanted, whether s.c. or i.m.
In each case, the curve to the right was
obtained with viable cells alone, and that
on the left when 106 lethally irradiated
tumour cells were added to each inoculum.
The full lines are cumulative Poisson distri-
butions, fitted to the data. The horizontal
bars show the 95% confidence limits on the
estimate of TD50.
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period of 60 days, and scored for the
presence or absence ofdetectable tumours.
The number of cells required for 5000
tumour takes was determined by a com-
puter program that employed the method
of Porter and Berry (1963).
In a series of initial experiments
(Fig. 2) the TD50 for s.c. implantation was
2100 cells. For i.m. implantation, fewer
cells were required, and the TD50 was
, 40 cells. In both sites there was
evidence ofa strong Revesz effect (Revesz,
1958); the addition of 106 lethally-
irradiated cells to each inoculum resulted
in TD50 values for s.c. and i.m. implanta-
tion that were close to 1 cell. Since the
ultimate TD50 for the implantation of a
pure population of clonogenic cells, one or
more of which gives a positive take, is
0 69 it is clear that the addition of
lethally-irradiated cells reduced the ob-
served TD50 values close to their ultimate
minimum. Throughout this work the
lethally-irradiated cells were exposed to
at least 10,000 rad of 60Co y-radiation.
Implants of lethally irradiated cells alone
were routinely made and in no case were
positive takes recorded.
The Table summarizes the TD50 values
obtained at various sites of implantation
in experiments spanning a period of 3
years. The s.c. and i.m. TD50 values were
always low, and the i.m. values were
consistently lower than the s.c. Three
experiments using intracerebral implanta-
tion showed that the TD50 without
lethally irradiated cells was probably
lower than for either of the other 2 sites,
but that when lethally irradiated cells
were added, the results were no better
than for s.c. implantation.
The effect of varying the number of
lethally irradiated cells was investigated
in the s.c. site (Fig. 3). As the number was
reduced from 106 to 105, the TD50
increased by more than a factor of 10;
increasing the lethally irradiated cells to
5 x 106 may have produced a slight
decrease in the TD50.
Two experiments were performed to
test the antigenicity of the B16 melanoma
TABLE. TD50 Estimations for B16
Melanoma
Method of
implanitation
Subcutaneous
Initracerebral
Intramuscular
With 106
Without lethally lethally
irra(liate(l cells irradiate(d cells
1540 7 6
2100 4 3
490 a 5
1 *4
2 2
2 -1
3-2
3 -8
3-'
21
3 -2
AMean 3 3.5
s.d. =18
9-9 1-7
4 0
39 1.1
I 0
0 7
1 3
2-1
1 5
I 1
1 3
1.1
1 3
1.0
1 0
0 7
Each determinationi has a
20%.
MeanI 1 17
s.(. =0 36
standlard error of
in the present mouse colony. In the first,
fragments of tumour were reduced to a
homogeneous brei in 5 volumes ofbalanced
salt solution. The brei was irradiated with
, 20 krad of y-irradiation and 0 1 ml
volumes were injected into the left hind
legs of recipient mice X 3 at 10-day
intervals. One week after the last injection
the mice were challenged with viable B16
cells, as in a normal end-point dilution
assay. Implants into the right hind legs
gave a TD50 of 1-0 (95oo confidence limits
0 4-2.4) while implants into the left hind
legs gave a TD50 of 241 (confidence limits
1*0-4.3). In the second experiment, the
immunization consisted of injections of
0*025 ml of the irradiated brei into 4
lymph-node sites (both axillae and both
inguinal regions) plus 01 ml i.p. This was
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FIG. 3.-The effect of different numbers of
lethally irradiated tumour cells on the
TD50 for s.c. implantation. The dashed line
shows the theoretical limit of 0-69:3 oni the
TD50, when any one viable cell can give
rise to a positive take.
repeated at the same intervals and the
challenge was again one week later. The
TD50 for hind leg implantation was then
0-9 cells (confidence limits 0-5-1.6) with
a simultaneous control in unimmunized
mice of 1
- cells (confidence limits 0 6-1 9).
Lung colony assay
The technique of lung colony assay was
as has been described for the Lewis lung
tumour (Hill and Stanley, 1975; Steel and
Adams, 1975). Viable cells were injected
i.v. together with 106 plastic microspheres
and 106 lethally irradiated tumour cells.
The mice were killed 21-25 days later, and
lung colonies were counted after fixation
of the lungs in Bouin's fixative. With
untreated tumour cells, there was a good
linear relationship between the number of
viable cells injected and the colonv count
(Fig. 4). It was noted that the B16 lung
colonies varied in colour from pale grey to
dark black, as described by Hill and
Stanley (1975). The lung cloning efficiency
has gradually improved over the 4-year
period in which this technique has been
used. In recent experiments, 2 x 103
untreated cells have produced 15-30
colonies.
Viable Cells Injected Ix103)
FIG. 4. Relation between the number oflung
colonies ini recipient, mice and the number
of viable cells injected, in one experiment.
Each injection of viable cells also contained
lethally irradiate(d cells and microspheres
(see text).
WVe have also found that the lung
cloning efficiency of the B16 melanoma
(and of the Lewis lung tumour) can be
greatly increased by treating recipient
mice with a maximum tolerated dose of
cyclophosphamide 3 days previously.
Lung cloning efficiencies of 14-18% have
thereby been achieved. The results ofthese
investigations are being prepared for
publication.
In vitro assay
The third assav that has been used for
the B16 melanoma is the in vitro assay
described by Courtenay (1976) and by
Stephens, Peacock and Steel (1977). This
was a double-layer soft-agar technique in
which rat red blood cells provided an
essential growth factor and the incuba-
tions were carried out in 50 02, 50 CO2
and 9000 N2. The colonies were counted at
14-18 days and the usual plating efficiency
was 30-5000.
Response of the B16 melanoma to cyclo-
phosphamide
The methods described here have been
employed in studies of the response of the
B16 melanoma to a number of chemo-
therapeutic agents, the results of which
will be the subject of a subsequent publi-
I
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cation. The results in the case of cyclo-
phosphamide (CY) will be described here
as an illustration of the fact that so far we
have found good agreement between the
3 methods.
Mice bearing i.m. B16 tumours were
treated with a single injection of 300 mg/
kg CY, a dose that killed 5005 of the
mice. When tumours were removed at
intervals after this treatment, they were
noticeably blacker than untreated
tumours. Cell suspensions and cytocentri-
fuge preparations were made, and in these
it was possible to identify 2 types of
melanin-containing cell: some were finely-
stippled with melanin granules, others had
large globules of melanin and these were
regarded as probably phagocytes. After
300 mg/kg CY there was an increase in
both types of cell, as well as in their
average melanin content. The total pro-
portion of melanin-containing cells in-
creased from a control value of60% to 130%
at 4 days, to 180% at 8 days and to 210%
at 12 days. A similar but not so marked
change was observed after local irradiation
with 2000 rad of 60Co y-rays.
The duration of cytotoxic action of a
single i.p. injection of CY was explored by
implanting B16 cells intramuscularly at
various intervals after 300 mg/kg of the
drug. Cell survival studies on previously
implanted tumours (see below) lead us to
expect that the effect of this dose would
be to increase the TD50 from 1-2 cells to
about 100 cells. When cells were implanted
I h after drug injection, the TD50 was 7 2
(confidence limits 4.2-12); by 2 h the
TD50 had returned to the control level,
thus the blood level of active metabolite
had fallen below the toxic limit.
The dose-response curve for cell survival
following the treatment of s.c. tumours
with CY is shown in Fig. 5. The drug was
given i.p., and the mice were killed 18 h
later. All three assays were used in this
study and although the range of values
determined by the in vitro assay tended to
be greater than for the in vivo assays there
was good agreement between them. The
dose-response curve is exponential, reach-
.c
0
0
C:
n1)
oo0 IoU 200 300
Cyclophosphomide Dose (rng/kg)
FicP. 5. The fraction of s3urviving clonogenic
cells in suspenisions from Bl 6 tumours
remove(l 18 h after single i.p. injections of
cyclophosphamidie. The fractions were
calculated as the ratio of the plating
efficiencies. 0 in vitro assay, A lung-
colony assay, F] end-point dilution assay.
ing 4 X 10-3 at the maximum tolerated
dose of 300 mg/kg.
DISCUSSION
The main purpose of this paper is to
indicate that in our hands the B1 6
melanoma has beenahighlytransplantable
tumour that can easily be assayed for
clonogenic cell survival. XVhen proper use
was made of the Revesz effect (Revesz,
1958) and when the i.m. site was used, the
number of cells required for 50%o tumour
takes was approximately 1-2, not far short
of the ultimate theoretical value of 0-69
cells (i.e. In 2). The mechanism of the
Revesz effect is not fully understood, but
Peters and Hewitt (1974) have suggested
that the main effect of lethally irradiated
tumour cells may be to induce a clotting
mechanism that prevents the implanted
cells from escaping from the implantation
site and thus becoming more vulnerable to
host defence mechanisms. Throughout the
work reported here, and in other experi-
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ments on the BI 6 melanoma, the relation
between tumour take probability and the
number of viable cells injected (Fig. 2)
was always consistent with a cumulative
Poisson distribution. This is an important
finding, for it implies that the implantation
sites have a uniform receptivity to
tumour transplantation and that, within
the critical range, the take probability
appears to depend, as theory would
predict, upon the presence of one or more
clonogenic cells.
The data presented in Fig. 3 indicate
that the number of added lethally irra-
diated cells is fairly critical. The TD50 rose
rapidly as the number was reduced below
]106; there was little room for further
improvement by using larger numbers
than this. A TD50 of approximately one
cell, in a situation where up to 106 live cells
can be implanted, means that the eind-
point dilution assay can measure the
suirviving fraction of clonogenic cells down
to about 10-6.
The lung colony assay has also per-
formed well with this tumour. The data
shown in Fig. 4 indicate a lung cloning
efficiency of 1-3 x 10-3 (i.e. one colonv
per 700 cells injected), in good agreemeint
with the results of Hill and Stanley (1975).
As indicated above, the lung cloning
efficiency has improved over a, period of
4 years, and recent work has indicated
that it can be greatly increased by
systemic treatment with CY.
The in vitro assav for clonogeniic B16
melanoma cells has been described else-
where (Courtenay 1976; Stephens et al.,
1977). The method is also able to measure
surviving fractions down to about 10-3
and it has the advantages of speed and
economy over the 2 in vivo techniques.
Nevertheless, the greater sensitivity of the
end-point dilutioni assav is an importaut,
factor when low levels of survival are to be
explored.
A single straight line has been drawn
through the survival data in Fig. 5. The
results obtained by the lung-colony assay
and end-point dilution assay are in
excellent agreement. Those obtained by
the in vitro assay show greater scatter, and
some points fall well below the results of
the other 2 assays. The difference is not,
however, statistically significant.
The agreement that we have found
between these 3 assays in the study of the
response of the B16 melanoma to CY
parallels the results that have been ob-
tained in this laboratory with the Lewis
lung tumour (Shipley et al., 1975; Steel
and Adams, 1975). The sensitivity of the
B]6 melanoma to CY is, however, lower
by a factor of 3 than the Lewis lung
tumour. With each of these tumours,
following a variety of cytotoxic agents,
the values of surviving fraction have
agreed well between the 3 assays. This
implies that the post-treatment survival
of treated cells is independent of whether
they are allowed to grow intramuscularly
in the lung, or in suspension in soft agar.
The cells that can be extracted from the
B16 melanoma are to some extent hetero-
geneous. Under the microscope they can
be seen to vary in melanin content, and it
is also possible to identify cells whose
melanin is aggregated into globules, which
we presume to be macrophages (Evans,
1972). WVhen the cells are allowed to grow
in the lung, the resulting nodules vary in
melanin content, as reported by Hill and
Stanley (1975). Our work with CY has
shown that in response to treatment the
tumour tissue becomes much blacker. This
is due partly to the conservation of
melaniin, released from dead cells and
taken up by macrophages, but also
perhaps to an increase in the melanin
content of cells that were producing
melanin.
The assays described here allow more
reliable estimates to be made of the
survival of clonogenic cells than are
possible from the analysis of tumour
regrowth curves. Griswold (1975) treated
s.c. implants of B16 melanoma with CY
and, by extrapolating the regrowth curves
by displacement of the growth curve for
untreated tumours, he deduced estimates
of surviving fraction. The survival curve
obtained in this way is about twice as
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steep as we have found, and its flattening
above 200 mg/kg led Griswold to suggest
that there was little therapeutic value in
doses exceeding this level. Some of the
possible reasons for discrepancies between
the results of cell cloning assays and
regrowth data have been set out elsewhere
(Stephens and Peacock, 1977).
We acknowledge with gratitude the
support and encouragement of Professor
L. F. Lamerton and Professor M. J.
Peckham and also the technical assistance
of Mr J. H. Peacock.
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